Transthyretin Amyloid Cardiomyopathy
Eidos Therapeutics Inc. focuses on clinical research in symptomatic transthyretin amyloid cardiomyopathy, with attention to disease control, cardiac function, and the safety and tolerability of acoramidis in people living with established ATTR-CM.
- Symptomatic ATTR-CM
- Cardiac amyloidosis
- Cardiovascular disease management
The sponsor also supports longer-term clinical follow-up in newly diagnosed patients, reflecting continued interest in the management of progressive amyloid-related heart disease.
Transthyretin Amyloidosis Prevention
Another major area of interest is prevention of transthyretin amyloidosis in asymptomatic carriers of pathogenic TTR variants, with research directed toward delaying or preventing the onset of clinical disease in individuals at inherited risk.
- Asymptomatic TTR variant carriers
- Hereditary amyloidosis
- Early intervention in ATTR risk
This includes attention to both ATTR-CM and ATTR-PN as clinically relevant outcomes in people who have not yet developed overt disease.
Long-Term Safety and Tolerability
The sponsor’s research portfolio includes extended observation of acoramidis in transthyretin amyloidosis, with emphasis on sustained safety, tolerability, and ongoing treatment experience across affected populations.
- Long-term safety
- Tolerability monitoring
- Extended treatment follow-up
These studies address both people with established ATTR-CM and those being monitored for future development of amyloid disease.
Inherited Amyloid Disease
Eidos Therapeutics Inc. is active in research on inherited forms of amyloidosis, particularly conditions linked to pathogenic TTR variants and their impact on the heart and peripheral nerves.
- Genetic TTR disorders
- Familial amyloidosis
- ATTR-related organ involvement
The clinical focus spans both diagnosed disease and presymptomatic risk, covering the spectrum of transthyretin-mediated illness.
